Person: Lorente Pérez, María Del Mar
Loading...
First Name
María Del Mar
Last Name
Lorente Pérez
Affiliation
Universidad Complutense de Madrid
Faculty / Institute
Ciencias Químicas
Department
Bioquímica y Biología Molecular
Area
Bioquímica y Biología Molecular
Identifiers
6 results
Search Results
Now showing 1 - 6 of 6
Item Targeting Cannabinoid Receptors in Brain Tumors(Cannabinoids and the brain, 2008) Velasco Díez, Guillermo; Carracedo, Arkaitz; Blázquez Ortiz, Cristina; Lorente Pérez, María Del Mar; Aguado Sánchez, Tania; Sánchez García, María Cristina; Galve Roperh, Ismael; Guzmán Pastor, Manuel; Köfalvi, AttilaCannabinoids, the active components of Cannabis sativa L., act in the body by mimicking endogenous substances — the endocannabinoids — that activate specific cell surface receptors. Cannabinoids exert various palliative effects in cancer patients. In addition, cannabinoids inhibit the growth of different types of tumor cells, including glioma cells, in laboratory animals. They do so by modulating key cell signaling pathways, mostly the endoplasmic reticulum stress response, thereby inducing antitumoral actions such as the apoptotic death of tumor cells and the inhibition of tumor angiogenesis. Of interest, cannabinoids seem to be selective antitumoral compounds as they kill glioma cells but not their nontransformed astroglial counterparts. On the basis of these preclinical findings, a pilot clinical study of Δ9-tetrahydrocannabinol (Δ9-THC) in patients with recurrent glioblastoma multiforme has been recently run. The fair safety profile of Δ9-THC, together with its possible growth-inhibiting action on tumor cells, may set the basis for future trials aimed at evaluating the potential antitumoral activity of cannabinoids.Item Stimulation of ALK by the growth factor midkine renders glioma cells resistant to autophagy-mediated cell death(Autophagy, 2011) Lorente Pérez, María Del Mar; Torres, Sofia; Salazar, María; Carracedo, Arkaitz; Hernández-Tiedra, Sonia; Rodríguez-Fornés, Fátima; García-Taboada, Elena; Meléndez, Bárbara; Mollejo, Manuela; Campos-Martín, Yolanda; Barcia Albacar, Juan Antonio; Guzmán Pastor, Manuel; Velasco Díez, Guillermo; Velasco Díez, GuillermoΔ9-tetrahydrocannabinol (THC), the main active component of marijuana, promotes cancer cell death via autophagy stimulation. We find that activation of the tyrosine kinase receptor ALK by its ligand midkine interferes with the signaling mechanism by which THC promotes autophagy-mediated glioma cell death.Item Down-regulation of tissue inhibitor of metalloproteinases-1 in gliomas: a new marker of cannabinoid antitumoral activity?(Neuropharmacology, 2008) Sánchez-Camacho Blázquez, Cristina; Carracedo, Arkaitz; Salazar Roa, María; Lorente Pérez, María Del Mar; Egia, Ainara; González-Feria, Luis; Haro Ramos, Amador De; Velasco Díez, Guillermo; Guzmán Pastor, Manuel; Guzmán Pastor, ManuelCannabinoids, the active components of Cannabis sativa L. and their derivatives, inhibit tumor growth in laboratory animals by inducing apoptosis of tumor cells and inhibiting tumor angiogenesis. It has also been reported that cannabinoids inhibit tumor cell invasiveness, but the molecular targets of this cannabinoid action remain elusive. Here we evaluated the effects of cannabinoids on the expression of tissue inhibitors of metalloproteinases (TIMPs), which play critical roles in the acquisition of migrating and invasive capacities by tumor cells. Local administration of Δ9-tetrahydrocannabinol (THC), the major active ingredient of cannabis, down-regulated TIMP-1 expression in mice bearing subcutaneous gliomas, as determined by Western blot and immunofluorescence analyses. This cannabinoid-induced inhibition of TIMP-1 expression in gliomas (i) was mimicked by JWH-133, a selective CB2 cannabinoid receptor agonist that is devoid of psychoactive side effects, (ii) was abrogated by fumonisin B1, a selective inhibitor of ceramide synthesis de novo, and (iii) was also evident in two patients with recurrent glioblastoma multiforme (grade IV astrocytoma). THC also depressed TIMP-1 expression in cultures of various human glioma cell lines as well as in primary tumor cells obtained from a glioblastoma multiforme patient. This action was prevented by pharmacological blockade of ceramide biosynthesis and by knocking-down the expression of the stress protein p8. As TIMP-1 up-regulation is associated with high malignancy and negative prognosis of numerous cancers, TIMP-1 down-regulation may be a hallmark of cannabinoid-induced inhibition of glioma progression.Item Cannabinoids and Gliomas(Molecular Neurobiology, 2007) Velasco Díez, Guillermo; Carracedo, Arkaitz; Blázquez Ortiz, Cristina; Lorente Pérez, María Del Mar; Aguado Sánchez, Tania; Haro, Amador; Sánchez García, María Cristina; Galve Roperh, Ismael; Guzmán Pastor, ManuelCannabinoids, the active components of Cannabis sativa L., act in the body by mimicking endogenous substances—the endocannabinoids—that activate specific cell surface receptors. Cannabinoids exert various palliative effects in cancer patients. In addition, cannabinoids inhibit the growth of different types of tumor cells, including glioma cells, in laboratory animals. They do so by modulating key cell signaling pathways, mostly the endoplasmic reticulum stress response, thereby inducing antitumoral actions such as the apoptotic death of tumor cells and the inhibition of tumor angiogenesis. Of interest, cannabinoids seem to be selective antitumoral compounds, as they kill glioma cells, but not their non-transformed astroglial counterparts. On the basis of these preclinical findings, a pilot clinical study of Δ9-tetrahydrocannabinol (THC) in patients with recurrent glioblastoma multiforme has been recently run. The good safety profile of THC, together with its possible growth-inhibiting action on tumor cells, justifies the setting up of future trials aimed at evaluating the potential antitumoral activity of cannabinoids.Item TRB3 links ER stress to autophagy in cannabinoid anti-tumoral action(Autophagy, 2009) Salazar Roa, María; Carracedo, Arkaitz; Salanueva, Íñigo J.; Hernández Tiedra, Sonia; Egia, Ainara; Lorente Pérez, María Del Mar; Vázquez, Patricia; Torres, Sofia; Iovanna, Juan L.; Guzmán Pastor, Manuel; Boya, Patricia; Guillermo Velasco; Velasco Díez, Guillermo; Velasco, GuillermoΔ9-tetrahydrocannabinol (THC), the main active component of marijuana, is being investigated as a potential anti-tumoral agent. We find that THC stimulates an endoplasmic reticulum (ER) stress-related signaling pathway, which activates autophagy via inhibition of the Akt/mTORC1 axis. We also show that autophagy is upstream of apoptosis in cannabinoid-induced cancer cell death and that activation of this pathway is necessary for the anti-tumoral action of cannabinoids in vivo.Item Loss of Tribbles pseudokinase-3 promotes Akt-driven tumorigenesis via FOXO inactivation(Cell Death and Differentiation, 2014) Salazar Roa, María; Lorente Pérez, María Del Mar; Garcia-Taboada, Elena; Pérez Gómez, Eduardo; Davila, Davila; Zuñiga, Patricia; Flores Landeira, Juana María; Rodriguez, Antonio; Hegedus, Zoltán; Mosen-Ansorena, David; Aransay, Ana María; Hernandez-Tiedra, Sonia; Lopez-Valero, Israël; Quintanilla, Miguel; Sanchez, Cristina; Iovanna, Juan; Dusetti, Nelson; Guzmán Pastor, Manuel; Francis, Sheila; Carracedo, Arkaitz; Kiss-Toth, Endre; Velasco Díez, GuillermoTribbles pseudokinase-3 (TRIB3) has been proposed to act as an inhibitor of AKT although the precise molecular basis of this activity and whether the loss of TRIB3 contributes to cancer initiation and progression remain to be clarified. In this study, by using a wide array of in vitro and in vivo approaches, including a Trib3 knockout mouse, we demonstrate that TRIB3 has a tumor- suppressing role. We also find that the mechanism by which TRIB3 loss enhances tumorigenesis relies on the dysregulation of the phosphorylation of AKT by the mTORC2 complex, which leads to an enhanced phosphorylation of AKT on Ser473 and the subsequent hyperphosphorylation and inactivation of the transcription factor FOXO3. These observations support the notion that loss of TRIB3 is associated with a more aggressive phenotype in various types of tumors by enhancing the activity of the mTORC2/AKT/FOXO axis